STING1 and non-small cell lung carcinoma: In the clinical setting, a number of effective small‐molecule STING agonists emerged, already under phase I‐III clinical trials, including ADU‐S100 (NCT03937141), BMS‐986301 (NCT03956680), and DMXAA specifically trialed in NSCLC (NCT00674102) combined with carboplatin and paclitaxel.38